More China Woes For GSK? CFDA Wades Into Ozanezumab Controversy
This article was originally published in PharmAsia News
Taking heat from critics amid a report that GSK may have conducted unethical trials for multiple sclerosis drug ozanezumab, China’s Center for Drug Evaluation conducts its own investigation.
You may also be interested in...
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.
With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.